Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Alaa W. Meshref"'
Publikováno v:
Urology. 48:747-750
Objectives To assess the potential difference in positive biopsy rates between four-sector and six-sector biopsy methods. Methods This computer-assisted analysis is based on the records of 156 consecutive patients previously diagnosed with T1c cancer
Autor:
Pierre I., Karakiewicz, Michel, Bazinet, Alaa W., Meshref, Armen G., Aprikian, Claude, Trudel, Samuel, Aronson, Mahmoud, Nachabé, François, Péloquin, Michelle S., Goyal, Louis R., Bégin, Mostafa M., Elhilali
Publikováno v:
The Canadian journal of urology. 4(1)
OBJECTIVE: The objective of this study was to determine the benefit of repeat transrectal ultrasound-guided prostatic biopsy (TRUSBx) among men with prior benign histology on digitally guided biopsy despite suspicious digital rectal examination (DRE)
Autor:
Michel Bazinet, Mahmoud Nachabe, Jean Dessureault, Mostafa M. Elhilali, Alaa W. Meshref, Armen Aprikian, Samuel Aronson, Louis R. Bégin, Steven A. Narod, Mark Plante, Claude Trudel, Francois Peloquin
Publikováno v:
The Journal of urology. 154(2 Pt 1)
We examine the association of family history and prostatic carcinoma.A total of 2,968 consecutive patients referred for prostate cancer detection responded to a questionnaire and underwent transrectal ultrasound examination with or without biopsy.Of
Autor:
Samuel Aronson, Alaa W. Meshref, Francois Peloquin, Louis R. Bégin, Armen Aprikian, Jean Dessureault, Claude Trudel, Mahmoud Nachabe, Mostafa M. Elhilali, Michel Bazinet
Publikováno v:
Urology. 45(6)
Objectives To determine the potential role of prostate-specific antigen (PSA) density (PSAD) in the early detection of prostate carcinoma if we apply age-specific PSA reference ranges (2.5 ng/mL or less for ages 40 to 49 years, 3.5 or less for ages 5
Autor:
Michel Bazinet, Louis R. Bégin, Mahmoud Nachabe, Mostafa M. Elhilali, Alaa W. Meshref, Claude Trudel, Francois Peloquin, Samuel Aronson
Publikováno v:
Urology. 43(1)
Significant controversies persist in regard to the need for systematic biopsies in patients with serum prostate-specific antigen (PSA) levels above 4 ng/mL (Hybritech assay), especially if they show no signs of prostatic cancer on digital rectal exam